Collaborations

MARS Sepsis Consortium 

(Clinicaltrials.gov identifier: NCT01905033)

2011 –  present: The MARS Sepsis Consortium is a prospective observational cohort study designed to produce molecular information relevant to sepsis diagnosis and management. Immunexpress is a full partner in the collaborative Consortium. The Consortium recruited 8,603 critical care patients with signs of Systemic Inflammatory Response Syndrome (SIRS) across two tertiary hospitals in the Netherlands: the Academisch Medisch Centrum (AMC) in Amsterdam, and the University Medical Centre Utrecht (UMCU). Immunexpress is continuing collaborative sepsis clinical research at both study sites.

 

Tom van der Poll, Clinical Advisor

Tom van der Poll is Professor of Medicine and Chair of the Department of Medicine in the Academic Medical Center, University of Amsterdam, the Netherlands. Van der Poll is board certified in Internal Medicine and Infectious Diseases. Van der Poll’s research focuses on pneumonia and sepsis, particularly on pathogenesis, the host response and biomarkers. He published > 800 articles on this topic. Van der Poll has served as a member of Data Safety and Clinical Monitoring Boards of several pivotal phase III sepsis and pneumonia trials evaluating immunomodulatory agents. He is a member (past Chair) of the International Sepsis Forum.

Seattle Children's Hospital

(Clinicaltrials.gov identifier: NCT02728401)

2013 – present: The Genotypes and Phenotypes in Pediatric SIRS and Sepsis (GAPPSS) study is a collaborative pilot study at the Seattle Children’s Hospital between Professor Jerry Zimmerman and Immunexpress. Immunexpress and the Seattle Children’s Research Institute are jointly funding this study.

Intermountain Health Care

2013- present: Intermountain Healthcare acted as the coordinating trial and data collection site for the FDA clearance studies of SeptiCyte™ technology, including the on-site real-time studies, and has a long history of interaction with Immunexpress. This collaboration has resulted in multiple papers and publications ranging from assay performance trials through to health econometric modeling.

 

Intermountain Health Care Collaborators

Todd L. Allen MD FACEP, Clinical Associate Professor at Stanford University School of Medicine, Senior Executive Medical Director, Healthcare Delivery Institute, and immediate past-Chair of the Emergency Department Development Team and Intermountain Healthcare. Dr. Allen is a Fellow of the American College of Emergency Physicians and the Attending Physician for the Department of Emergency Medicine at the Intermountain Medical Center as well as at the Department of Emergency Medicine, LDS Hospital. Dr. Todd Allen is the Assistant Professor, Adjunct Track in the Department of Surgery, Division of Emergency Medicine, University of Utah-Salt Lake City. Dr. Allen is the Chair for the Emergency Department Development Team in the Intensive Medicine Clinical Program at Intermountain Healthcare and is responsible for design and implementation of team goals and projects including projects on sepsis, implementation of pre-hospital 12-lead ECGs, and stroke bundles.

 

 

Bert K. Lopansri, MD, FIDSA is a board certified, academic Infectious Diseases Specialist at Intermountain Healthcare hospitals. He serves as Chief of the Intermountain Division of Infectious Diseases and Medical Director for the Intermountain Central Microbiology Laboratory. He also directs the Infectious Diseases Research and Epidemiology Laboratory located at LDS Hospital. His research interests are in diagnostic microbiology and he has participated in clinical trials evaluating novel, rapid, molecular tests. He also has interests in the epidemiology and outcomes of infections from Clostridium difficile and antibiotic resistant bacteria. Dr. Lopansri is an Associate Professor of Medicine at the University of Utah School of Medicine.

 

 

Russell Miller, MD, MPH, FCCM is Chair of the Critical Care Development Team for Intermountain Healthcare and Director of the Respiratory ICU at Intermountain Medical Center. He provides care to patients in the Respiratory ICU at Intermountain Medical Center and maintains an academic focus in sepsis research. Dr. Miller co-leads a national quality improvement effort to standardize ICU care bundles and is a committee member for the Prevention and Early Treatment of Acute Lung injury (PETAL) Network, a collaborative multicenter research group funded by the NIH/NHLBI. Dr. Miller also directs quality improvement and best practice development within critical care for Intermountain Healthcare.

University College London Hospital

2011 – present: University College London and Immunexpress continue to collaborate in prospective observational cohort studies including in pneumonia, immunocompromised sepsis patients, UTIs, and on validation of gene expression biomarkers for bacterial and viral sepsis.

 

Mahdad Noursadeghi is Professor of Infectious Diseases at University College London and Consultant in Infectious Diseases and Internal Medicine at University College London Hospital NHS Foundation Trust. He leads a research group, funded by the Wellcome Trust, UK Medical Research Council and UK National Institute for Health Research, focussing on systems level analysis of host responses to infection, with the aim of discriminating between protective and pathogenic immune responses that may inform the development of new therapies and novel approaches to patient stratification.